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Abstract
Background: Hepatitis E is a liver disease caused by a small RNA virus known as hepatitis E virus (HEV). Four major
genotypes infect humans, of which genotype 1 and 2 (HEV-1, HEV-2) are endemic mainly in Asia and responsible
for waterborne epidemics. HEV-3 and HEV-4 are widely distributed in pigs and can be transmitted to humans
mainly by undercooked meat, and contact with pigs. HEV-3 is the main genotype in industrialised countries with
moderate climate conditions and object of this debate.
Main text: Whereas an HEV-3 infection in healthy humans is mostly asymptomatic, HEV-3 can induce chronic
infection in immunocompromised individuals and acute-on-chronic liver failure (ACLF) in patients with underlying
liver diseases. The number of reported cases of HEV-infections in industrialised nations increased significantly in the
last years. Since HEV-3 has been transmitted by blood transfusion to other humans, testing of blood donors has
been introduced or introduction is being discussed in some industrialised countries. In this article we summarise
the arguments in favour of testing all blood donations for HEV-3.
Conclusion: The number of HEV infection in the population and the possibility of HEV transmission by blood
transfusion are increasing. Transmission by blood transfusion can be dangerous for the recipients considering their
immunosuppressive status, underlying disease or other circumstances requiring blood transfusion. This argues in
favour of testing all blood donations for HEV-3 to prevent transmission.
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Background
Blood transfusion is a lifesaving procedure to replace
blood cells or plasma lost through severe bleeding, e.g.,
during surgery when blood loss occurs. It is also used in
anemic patients as an essential part of treatment. In 2014,
nearly 3.8 million units of packed red blood cells, 485,000
thrombocyte or platelet concentrates, and 796,000 units
plasma were used for transfusions in Germany [1].
In order to avoid transmission of microorganisms from
the donor to the recipient, strong regulations are in force.
All donations in Germany must be tested for antibodies
against human immunodeficiency virus 1 (HIV-1) and
HIV-2, against human hepatitis C virus (HCV), against
human hepatitis B core antigen (HBcAg), as well as for
human hepatitis B surface antigen (HBsAg) and for the
genomes of HCV and HIV using nucleic acid testing
(NAT) [2]. Thus, transfusion-associated transmissions of
these viruses are rare [3]. Also transmission of other vi-
ruses including West Nile virus (WNV), human T cell
lymphotropic virus (HTLV), rabies virus as well as of para-
sites (mainly malaria) and bacteria has been reported with
a very low risk [3].
In Germany, testing of all blood donations for HEV is
in preparation to be introduced. A nationwide HEV
RNA universal screening of blood donations has already
been introduced in Ireland, the UK, Japan and the
Netherlands. In Switzerland, nucleic acid screening of all
blood products for HEV started in November 2018 [4].
Blood authorities in Greece, Portugal, Italy, France and
Spain are evaluating the situation [5]. Recently, the re-
sponsible German authority, the Paul-Ehrlich-Institut,
recommended testing all blood donations for HEV.
Here, we discuss the relative risk, posed by HEV trans-
mission via transfusion and summarise the major argu-
ments recommending the testing of all blood donations
for HEV.
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HEV - biology and prevalence
HEV is a single-stranded, positive-sense RNA virus clas-
sified in the family Hepeviridae [6]. The HEV particles
present in feces and bile are nonenveloped, while those
in circulating blood and culture supernatants are cov-
ered with a cellular membrane, similar to enveloped vi-
ruses and called quasi-enveloped [7]. There are eight
genotypes of HEV: HEV-1 and HEV-2 are primarily
human viruses, whereas HEV-3 and HEV-4 were found
in pigs, humans and other animals. HEV-5 and HEV-6
were described only in wild boars in Japan, HEV-7 was
found in a dromedary camels and HEV-8 in Bactrian
camels [8]. HEV-1 and HEV-2 are endemic in regions in
Asia and Africa, the major source of infection is contam-
inated water (for review see [6]). HEV-3 and HEV-4 are
zoonotic viruses transmitted to humans mainly by direct
contact with pigs or eating undercooked pork. Seropre-
valences of HEV-3 in domestic pigs were estimated be-
tween 5 and 100% [9]. The detection of viral RNA and
virus-specific antibodies depends significantly on the
analysed pig material, the age of the animals and the de-
tection methods (PCR, real-time PCR, ELISA and
Western blot analysis) [10–12].
Usually pigs are infected at an early age after the loss
of the maternal antibodies, a peak of viral excretion in
pig fecal samples is detected between week three and
eight after weaning, the excretion decreases with the ap-
pearance of antibodies. Detection of viral RNA in serum
samples is less frequent than in liver and fecal samples
[9]. HEV-7 was also found in a liver transplanted patient
regularly consuming camel meat and milk [13]. HEV in-
fections have little impact on animal health, the animals
have no obvious symptoms, however co-infection with
other viruses may increase the amount and the duration
of HEV secretion or induce even fatal diseases [14].
Transmission of HEV-3 in pigs and humans
Whereas oral-fecal transmission is the major way of
HEV transmission in pigs, transmission via the pla-
centa was also detected [15]. Contact with pigs and
the consumption of undercooked pork meat is the
main way of transmission of HEV-3 to humans. HEV
was also found in wild boars [16–18] and screening
of wild boar hunters, forest workers and pet pig
holders gave good evidence that HEV is transmitted
by contact with pigs and wild boars [19, 20]. Many
reports describe the detection of HEV RNA in pig
liver, meat and meat products intended for human
consumption (for review see [6]). In addition, HEV
infections have been reported after consumption of
shellfish and vegetables, obviously due to a conta-
mination with pig manure [21–23]. Transmission has
also been reported after consumption of wild boar
meat [24].
The seroprevalence of HEV-3 in the general popula-
tion of Western countries has been shown to differ, par-
tially due to the use of different assays [10, 11, 25].
The HEV seroprevalence and viremia in blood donors
was also shown to differ in Western countries (Table 1)
[26–40]. In the Southwest of France even 52% positive
donors were found, here mainly due to the consumption
of undercooked figatellu liver sausages [27]. Studies in
Germany showed an anti-HEV IgG prevalence of 6.8%
[41], the rate of HEV-positive donations was 1:4525 [42]
and hepatitis E viraemia was found at a relatively high
rate of 0.12% among blood donors in 2018 [42]. In com-
parison with Europe and the United States, the sero-
prevalence was lower in Latin America [43, 44]. In
Switzerland on average 29.4% of blood samples were
positive, the seroprevalence increased with age (30.7% of
males and 34.2% of women over 60 years old) [4]. An in-
crease of seropositive donors with age was also observed
in France [27].
Due to the high prevalence in blood donors, transmis-
sion of HEV by blood transfusion has been observed [4,
26, 32, 33, 44–47], but not all patients receiving HEV-
positive blood got infected [33, 44, 46]. The infectivity of
HEV-contaminated components for transfusion was in
one study 50% [48] and seems to depend upon the virus
load [33, 46]. HEV transmission depends not only on
the virus load, but also on the blood component given
and on the presence of antibodies in the preparation
[33]. Overall, donations containing antibody were less
likely to transmit. HEV transmission was also associated
with organ transplantation, but only in single cases [49–
51]. The prevalence of persistent HEV infection in
patients with solid organ transplantation in Western
Europe varies between 0.7 and 3.2% [52]. The different
observed incidences strongly depend on the respective
antibody test applied in the respective study.








Germany 29.5 1:1200 [26] 2012
France 22.4 1:2218 [27, 28] 2014, 2016
1:744 [29] 2017
The Netherlands 27.0 1:2671 [30] 2012
1.600 [31] 2015
England 12.0 1:2848 [32] 2011
1:7000 [33] 2012
Scotland 4.7 1:14520 [34] 2013
Denmark 1:2330 [35] 2016
Spain 19.9 1:3333 [36] 2015
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Most infections of immunocompetent humans with
HEV-3 are asymptomatic, in rare cases a mild anicteric
illness and a moderate hepatitis were reported. In some
cases an acute hepatitis by red blood cell transfusion was
described in immunocompetent subjects [53]. In a pa-
tient with thrombotic thrombocytopenic purpura (TTP),
an acute HEV infection by cryosupernatant plasma trig-
gered exacerbation of the TTP [54]. HEV infection
becomes chronic in patients who are immunosuppressed
(HIV-infection, transplantation, chemotherapy, rheum-
atic diseases), however chronic HEV infection was also
observed in an immunocompetent patient with a history
of systemic lupus erythematosus [55]. Neurological man-
ifestations caused by HEV infections have been reported,
but they are still not well analysed [56]. In patients with
underlying liver disease, a severe hepatitis occurs [19].
HEV may be an immunosuppressive virus. There is evi-
dence in a pig model of chronic HEV infection that
HEV actively suppressed cellular immune responses [57]
and increased levels of the immunosuppressive IL-10
have been found in HEV-infected individuals [58].
HEV infected individuals can be treated with the anti-
viral ribavirin and for prophylaxis, a human vaccine, at
least against HEV-1, was developed. However the efficacy
against HEV-3 has still not been specifically tested and
this vaccine has no approval outside of China [59, 60].
There is evidence that the number of reported HEV-3 in-
fections increases not only due to greater awareness and
better testing, but also due to a real increase in infection
rates [31, 36, 61]. However, in Switzerland the number of
human infections declined [40]. Within the specified re-
gion of the Swiss Bern canton, overall prevalence has de-
clined over two decades from 30.3% in 1997/98 to 27.0%
in 2006 and 22.3% in 2015/6 [4].
The need of testing of all blood donations
As mentioned above, several reports have described
transfusion-transmitted HEV infections [4, 26, 32, 33, 42,
44, 46, 47]. In one case, HEV transmission was associated
with fatal hepatitis in a Japanese cancer patient [62]. How-
ever, it is obvious that the risk of infection through meat
consumption is much higher compared with transmission
by blood transfusion. Screening blood donations will not
prevent most cases of HEV transmission, but it will signifi-
cantly reduce the risk for the transfusion recipients, which
are either immunosuppressed and/or suffering from differ-
ent diseases. In addition, there is a great difference between
a person who takes up the virus orally and a person who
gets infected intravenously. In the case of oral uptake there
may be some protection by the acidic environment of the
stomach and the mucosal barrier in the gut. Immunocom-
promised patients need often multiple transfusions, which
increases the risk from transmission [46].
HEV was detected in 1 of 815 blood donations in
Germany [45] and is 100 times more prevalent compared
with HIV, HCV and HBV combined. Risk estimations con-
sidering both, the HEV prevalence and clinical risk for im-
munocompromised patients [63, 64] led to introduction of
blood screening for HEV in the Netherlands and Germany.
Analysing the cost-effectiveness of the screening of blood
donations for HEV in the Netherlands, the authors came to
the conclusion that preventing HEV transmission by
screening of blood donations appears not excessively ex-
pensive compared to other blood screening measures [63].
However, since only a small number of HEV infections are
due to blood transfusions, the overall impact on HEV dis-
ease burden will be small [63]. To reduce de novo infec-
tions in general, several strategies have been proposed [65].
It may be assumed that it may be sufficient to test only
the blood donations for people at risk, e.g., immunosup-
pressed organ transplant recipients and recipients of
haematopoietic stem cells. Such a limited testing seemed
cost effective while protecting patients at major risk. How-
ever, there are several arguments for universal screening
of all blood donations. First, the category “people at risk”
is difficult to define due to individual variability. Cancer
patients under chemotherapy, HIV infected individuals,
and patients with rheumatoid arthritis and other rheum-
atic diseases under immunosuppressive treatment should
also be included. The fatal outcome of a transfusion-
transmitted infection of a cancer patient in Japan [62] un-
derlines that the risk-group should not be limited to trans-
plant patients alone. Second, even immunocompetent
patients may suffer from acute HEV-infection or induced
complications under circumstances requiring blood or
plasma transfusion [54, 55, 66, 67]. Third, the handling of
two separate types of blood donations would increase lo-
gistical cost and may even lead to product losses due to
the stockpiling of tested and non-tested donations. For ex-
ample, in the case more tested material is required, stored
non-tested material will not be used and may expire and
vice versa. Fourth, it may be very difficult or even impos-
sible for a physician to assign a patient to an HEV risk in
an emergency requiring transfusion.
Conclusion
HEV-contaminated food is the main source of HEV trans-
mission to humans in Europe and other industrialised
countries with moderate climate conditions. However,
transmission by blood transfusion can be dangerous for the
recipients considering their immunosuppressive status,
underlying disease or other circumstances requiring blood
transfusion. Several of the arguments discussed above in
detail argue in favour of testing all blood donations for
HEV-3 to prevent transmission. Based on these arguments,
blood donor testing has been introduced in several indus-
trialised countries, including recently Germany.
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